ZA947782B - Stable protein: Phospholipid compositions and methods - Google Patents
Stable protein: Phospholipid compositions and methodsInfo
- Publication number
- ZA947782B ZA947782B ZA947782A ZA947782A ZA947782B ZA 947782 B ZA947782 B ZA 947782B ZA 947782 A ZA947782 A ZA 947782A ZA 947782 A ZA947782 A ZA 947782A ZA 947782 B ZA947782 B ZA 947782B
- Authority
- ZA
- South Africa
- Prior art keywords
- protein
- methods
- compositions
- stable protein
- phospholipid compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13241393A | 1993-10-06 | 1993-10-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA947782B true ZA947782B (en) | 1995-05-17 |
Family
ID=22453938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA947782A ZA947782B (en) | 1993-10-06 | 1994-10-05 | Stable protein: Phospholipid compositions and methods |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP0671905B1 (xx) |
JP (1) | JP2852127B2 (xx) |
KR (1) | KR100372006B1 (xx) |
CN (1) | CN1206982C (xx) |
AT (1) | ATE222752T1 (xx) |
AU (1) | AU683698B2 (xx) |
CA (1) | CA2150939C (xx) |
CZ (1) | CZ290029B6 (xx) |
DE (1) | DE69431236T2 (xx) |
DK (1) | DK0671905T3 (xx) |
ES (1) | ES2184768T3 (xx) |
FI (1) | FI116271B (xx) |
HK (1) | HK1010341A1 (xx) |
HU (1) | HUT72326A (xx) |
IL (1) | IL111170A (xx) |
NO (1) | NO314064B1 (xx) |
NZ (1) | NZ274705A (xx) |
PT (1) | PT671905E (xx) |
RU (1) | RU2119791C1 (xx) |
WO (1) | WO1995009611A2 (xx) |
ZA (1) | ZA947782B (xx) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874075A (en) * | 1993-10-06 | 1999-02-23 | Amgen Inc. | Stable protein: phospholipid compositions and methods |
US7972593B2 (en) | 2004-06-10 | 2011-07-05 | Saint Louis University | Delivery of therapeutic agents to the bone |
US7863238B2 (en) | 2004-06-10 | 2011-01-04 | Saint Louis University | Proteins with an attached short peptide of acidic amino acids |
JP2006248978A (ja) * | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
EP2259768B1 (en) | 2008-04-08 | 2019-05-22 | Merck Patent GmbH | Compositions containing cyclic peptides and methods of use |
SG11201407812SA (en) * | 2012-05-31 | 2014-12-30 | Agency Science Tech & Res | Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives |
EP3135297A4 (en) * | 2014-04-04 | 2018-02-07 | Osaka University | Drug delivery promoter containing substance for activating lysophospholipid receptors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4208527A1 (de) * | 1992-03-17 | 1993-09-23 | Max Planck Gesellschaft | Liposomen mit negativer ueberschussladung |
JPH06247842A (ja) * | 1993-02-23 | 1994-09-06 | Green Cross Corp:The | リポソーム組成物の製造方法 |
-
1994
- 1994-09-29 DE DE69431236T patent/DE69431236T2/de not_active Expired - Fee Related
- 1994-09-29 HU HU9502053A patent/HUT72326A/hu unknown
- 1994-09-29 KR KR1019950702281A patent/KR100372006B1/ko not_active IP Right Cessation
- 1994-09-29 RU RU95117866A patent/RU2119791C1/ru not_active IP Right Cessation
- 1994-09-29 NZ NZ274705A patent/NZ274705A/en not_active IP Right Cessation
- 1994-09-29 CA CA002150939A patent/CA2150939C/en not_active Expired - Fee Related
- 1994-09-29 ES ES94929959T patent/ES2184768T3/es not_active Expired - Lifetime
- 1994-09-29 DK DK94929959T patent/DK0671905T3/da active
- 1994-09-29 AU AU79239/94A patent/AU683698B2/en not_active Ceased
- 1994-09-29 PT PT94929959T patent/PT671905E/pt unknown
- 1994-09-29 EP EP94929959A patent/EP0671905B1/en not_active Expired - Lifetime
- 1994-09-29 JP JP7510908A patent/JP2852127B2/ja not_active Expired - Lifetime
- 1994-09-29 CZ CZ19951438A patent/CZ290029B6/cs not_active IP Right Cessation
- 1994-09-29 CN CNB941911012A patent/CN1206982C/zh not_active Expired - Fee Related
- 1994-09-29 AT AT94929959T patent/ATE222752T1/de not_active IP Right Cessation
- 1994-09-29 WO PCT/US1994/011081 patent/WO1995009611A2/en active IP Right Grant
- 1994-10-04 IL IL11117094A patent/IL111170A/xx not_active IP Right Cessation
- 1994-10-05 ZA ZA947782A patent/ZA947782B/xx unknown
-
1995
- 1995-06-02 NO NO19952210A patent/NO314064B1/no not_active IP Right Cessation
- 1995-06-05 FI FI952738A patent/FI116271B/fi active IP Right Grant
-
1998
- 1998-10-17 HK HK98111293A patent/HK1010341A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL117690A0 (en) | Stable protein: phospholipid compositions and methods | |
ES8507573A1 (es) | Procedimiento para la fabricacion de fracciones de acido hialuronico | |
AU5018693A (en) | Sustained-release protein formulations | |
AU1162099A (en) | Prolamin-plant polar lipid combination, preparation method and applications | |
WO1997010851A3 (en) | Nucleic acid delivery vehicle | |
CA2039491A1 (en) | Stable compositions for parenteral administration and method of making same | |
IL122486A (en) | Process for making liposome preparation | |
CA2002540A1 (fr) | Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees procede de preparation du facteur ix et produits obtenus correspondants | |
AU3530997A (en) | Use of complex lipids as stabilising additives to pharmaceutical preparations of digestive enzyme mixtures | |
ES2077904T3 (es) | Obtencion y uso de preparados estables de liposomas en forma de pequeñas particulas. | |
IL111170A0 (en) | Stable protein: phospholipid compositions and methods | |
RU95117866A (ru) | Фосфолипидные композиции и способ их получения | |
DE69520231D1 (de) | Liposomzubereitungen enthaltend hybrid-interferon |